What Happened? Shares of global pharmaceutical company Merck (NYSE:MRK) jumped 4.1% in the afternoon session after Wells ...

Merck (MRK) has quietly pulled ahead of many pharma peers, with the stock climbing about 22% over the past month and 20% in the past 3 months, drawing fresh attention to its valuation. See our latest ...

Merck & Co has a lower P/E than the aggregate P/E of 57.45 of the Pharmaceuticals industry. Ideally, one might believe that ...

Pharmaceutical stock Merck & Co (NYSE:MRK) is up 4% at $101.64 at last glance, after an upgrade from Wells Fargo to "overweight" from "equal weight," with a price-target hike to $125 from $90. The ...

Merck’s MRK shares have risen 9.6% in a month. The company’s stock declined after it announced third-quarter results. Though it beat estimates for both earnings and sales, its blockbuster PD-L1 ...

Merck (MRK) shares have ticked higher this week, catching the interest of investors who follow the big names in healthcare.

Investing.com -- Merck shares received an upgrade at Wells Fargo, with analyst Mohit Bansa lifting the stock to Overweight ...

Merck (MRK) stock in focus as the company urges shareholders to reject a mini-tender offer which stands at a 25% discount to ...